Welcome to our dedicated page for OTIC news (Ticker: OTIC), a resource for investors and traders seeking the latest updates and insights on OTIC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OTIC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OTIC's position in the market.
Otonomy, Inc. (Nasdaq: OTIC) announced significant updates on its product pipeline and financial outlook. The company is preparing to report results for OTO-413 in hearing loss and OTO-313 in tinnitus in 2022. Otonomy has approximately $77 million in cash, expected to sustain operations into the second half of 2023. Key milestones include Phase 2 trial results for OTO-313 and OTO-413, and the initiation of a Phase 3 program for OTO-313 in 2023. The company aims to address treatment gaps for tinnitus and hearing loss, emphasizing its commitment to innovation in neurotology.
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company focused on neurotology, will participate in the H.C. Wainwright BioConnect Virtual Conference. A pre-recorded presentation from the management team will be available on January 10, 2022, starting at 7 a.m. ET / 4 a.m. PT. Interested viewers can access the presentation via the conference website or through the company's Events page.
Otonomy’s innovative drug delivery technology targets hearing loss and tinnitus, aiming to meet critical medical needs.
Otonomy, Inc. (Nasdaq: OTIC) announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021. The company will feature a pre-recorded fireside chat available from 10 a.m. ET / 7 a.m. PT. A link to the chat can be found on Otonomy's website. Additionally, Otonomy will hold one-on-one investor meetings on December 1, 2021, arranged exclusively through Piper Sandler. Otonomy focuses on developing innovative therapeutics for neurotology, particularly addressing hearing loss and tinnitus.
Otonomy, Inc. (Nasdaq: OTIC) reported a cash position of $87.1 million as of September 30, 2021, with increased operating expenses of $12.5 million for Q3 2021. The Phase 2 trial of OTO-313 for tinnitus is ongoing with results expected in mid-2022, while the OTO-413 Phase 2a cohort is ahead of schedule, with anticipated results in early Q2 2022. The IND filing for OTO-825 is expected in the first half of 2023. Operating expenses are projected between $46-$48 million for 2021. The company anticipates having sufficient funds to support operations into the second half of 2023.
Otonomy, Inc. (Nasdaq: OTIC) announced it will release its third quarter 2021 financial results and provide a corporate update on November 10, 2021, at 4:30 p.m. ET. Investors can join the call by dialing (877) 305-6769 for domestic or (678) 562-4239 for international participants, using conference ID 3812898. A live webcast will also be available on the company's investor relations website. Otonomy focuses on developing innovative therapeutics for neurotology, utilizing drug delivery technology to address hearing loss and tinnitus.
Otonomy, Inc. (Nasdaq: OTIC) announced positive top-line clinical results for OTO-313 and OTO-413 aimed at treating tinnitus and hearing loss, respectively. The presentations will occur at Neuroscience 2021, showcasing the breadth of their pipeline and supportive data for OTO-825 gene therapy and OTO-510 otoprotection program. The company emphasizes their innovative drug delivery technology for sustained local administration, addressing key unmet medical needs.
Otonomy, Inc. (OTIC) announced positive results from its OTO-313 Phase 1/2 clinical trial, published in Otology & Neurotology. The study demonstrated that 43% of OTO-313 patients experienced a clinically meaningful reduction in tinnitus severity compared to 13% in the placebo group. OTO-313, an NMDA receptor antagonist, is designed to treat tinnitus following cochlear injury. Patient enrollment for the ongoing Phase 2 trial is progressing, with topline results expected in mid-2022, marking a significant advancement for tinnitus treatment options.
Otonomy, Inc. (Nasdaq: OTIC) announced the presentation of clinical results from its OTO-413 Phase 1/2 trial at the AAO-HNS Annual Meeting in Los Angeles on October 3, 2021. The results will be shared by Dr. Peter G. Volsky, highlighting the treatment's potential for patients suffering from speech-in-noise hearing impairment, a common issue in noise-induced and age-related hearing loss. Otonomy focuses on innovative therapeutics for neurotology, leveraging unique drug delivery technology to address significant medical needs in hearing loss and tinnitus.
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company focused on innovative neurotology therapeutics, will participate in two virtual conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will feature a pre-recorded fireside chat available on-demand from September 13, 2021, at 7 a.m. ET. The Cantor Global Healthcare Conference will have a live presentation on September 29, 2021, at 2:40 p.m. ET. Both presentations will be accessible via the Events page on Otonomy's website.
Otonomy, Inc. (Nasdaq: OTIC) announced the appointment of Jill Broadfoot to its board of directors, enhancing its strategic and financial expertise in the biopharmaceutical sector. Broadfoot, who brings experience as CFO at various companies including aTyr Pharma and Vical, expressed enthusiasm for Otonomy's neurotology focus and pipeline advancement. CEO David A. Weber highlighted her strong qualifications as integral to the company's growth trajectory and progress toward clinical milestones.
